Primary Neuroendocrine Carcinoma of the Breast: A Case Report

Yaren, Arzu; Kelten, Canan; Akbulut, Metin; Teke, Zafer; Düzcan, Ender; Erdem, Ergün

doi:10.1177/030089160709300516

Cited by 11 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of hormonal treatment in this tumor has yet to be determined. In certain studies, patients with NE carcinoma of the breast were treated with tamoxifen or aromatase inhibitors (2,6,7). In the present study, hormonal therapy was planned for all of the patients who positively expressed estrogen and/ or progesterone receptor.…”

Section: Discussionmentioning

confidence: 98%

“…The limited number of cases available make it difficult to adequately assess prognosis of this rare tumor. In addition, a standard approach to the management of this disease has yet to be established, since only a few case reports have indicated therapeutic options (2,(6)(7)(8). Therefore the aim of this study was to investigate management of NE carcinoma of the breast.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of neuroendocrine carcinomas of the breast: A rare entity

Yıldırım

2011

Oncol Lett

View full text Add to dashboard Cite

Abstract. Neuroendocrine (NE) carcinoma of the breast is extremely rare and constitutes less than 0.1% of all breast tumors. Only a few studies are currently available in the literature and a standard approach to treating this tumor has yet to be established. The aim of this study was to apply pathological treatment modalities in clinical practice and to select the most appropriate treatment accordingly. Six female patients were diagnosed with primary NE carcinoma of the breast. The patients underwent modified radical mastectomy with axillary dissection. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies [neuron-specific enolase (NSE), chromogranin, synoptophysin, estrogen and progesterone receptor, c-erbB2 and Ki-67]. The results showed that tumor size ranged from 2 to 4.5 cm in diameter. Lymph node metastasis was detected in 4 (67%) patients. Estrogen and progesterone receptor expression was found in 5 (83%) patients. None of the patients expressed c-erbB2. Chromogranin was found to be positive in 5 (83%) patients.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Management of neuroendocrine carcinomas of the breast: A rare entity

Yıldırım

2011

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Tumor cells form nests, islands, and alveolar-like structures surrounded by delicate fibrovascular stroma [5–7, 11]. Immunohistochemically tumor cells are positive for cytokeratin, estrogen receptors (ER), progesterone receptors (PR), neuron specific enolase (NSE), chromogranin A, and/or synaptophysin [4–7, 18, 21].…”

Section: Discussionmentioning

confidence: 99%

“…Some authors believe that the most important factor is tumor grade (G) and there is no difference in prognosis of NECB and other mammary carcinomas [25, 26]. Important features for good prognosis are early stage, absence of lymph-node metastases, and positive ER and PR status [5, 10, 26]. …”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of the Breast: Histopathological Criteria, Prognostic Factors, and Review of the Literature

Marinova

Malinova

Vicheva

2016

Case Reports in Pathology

View full text Add to dashboard Cite

We present here a case of a 42-year-old woman diagnosed with primary neuroendocrine carcinoma of the breast (NECB). We discuss the importance of histological criteria for primary neuroendocrine mammary carcinoma, established by WHO in 2003 and 2012. After an overview of different cases of primary neuroendocrine carcinoma of the breast published in the literature, we present information about differential diagnosis, prognostic factors, and surgical and adjuvant treatment. Prognosis of NECB is not different from that of other invasive breast carcinomas and the most important prognostic factor is tumor grade (G). There is no standard treatment and patients should be treated similarly to patients with invasive ductal carcinoma, NOS (not otherwise specified), whose choice of therapy depends on tumor's size, degree of differentiation, clinical stage, and hormonal status.

show abstract

“…8 Histologically, the morphological features of NEC are similar to those of lung and extrapulmonary sites, such as uterine cervix carcinoma and cancers of the pancreas, larynx, and gastrointestinal tract. 9 With regard to tumors observed by routine light microscopy, several distinct morphologic subtypes have been recognized. In 2003, the World Health Organization divided breast primary C The tumor cells in the right breast had an even round to oval shape, fi nely granular nuclear chromatin, and generally inconspicuous nucleoli (HE, ×200).…”

Section: Discussionmentioning

confidence: 99%

Bilateral primary breast neuroendocrine carcinoma in a young woman: Report of a case

Zhang

Chen

2011

Surg Today

View full text Add to dashboard Cite

Bilateral breast carcinoma accounts for approximately 5% of all patients with breast cancer, while neuroendocrine breast carcinomas comprise less than 5% of invasive breast carcinomas. In addition, most patients with breast neuroendocrine carcinomas are older. Therefore, bilateral primary breast neuroendocrine carcinoma at a young age is extremely rare. We herein report bilateral neuroendocrine carcinoma of the breast in a 29-year-old woman who underwent bilateral lumpectomy with the initial symptom of bilateral nipple discharge. Grossly, the lesions in both breasts were masses with infinite margins. Histologically, this case was consistent with primary neuroendocrine carcinoma arising in bilateral breasts. Cells from both breast tumors were positive for chromogranin A, neuron-specific enolase, synaptophysin, cytokeratin 7, estrogen receptor, and progesterone receptor, and negative for Her2, cytokeratin 34β12, cytokeratin 5/6, smooth muscle actin, p63, S-100 protein, and p53. The Ki67 and NE proliferative indices were below 1%. To the best of our knowledge, this is the first reported case in China of bilateral primary neuroendocrine carcinoma presenting in a young woman.

show abstract

Primary Neuroendocrine Carcinoma of the Breast: A Case Report

Cited by 11 publications

References 13 publications

Management of neuroendocrine carcinomas of the breast: A rare entity

Management of neuroendocrine carcinomas of the breast: A rare entity

Primary Neuroendocrine Carcinoma of the Breast: Histopathological Criteria, Prognostic Factors, and Review of the Literature

Bilateral primary breast neuroendocrine carcinoma in a young woman: Report of a case

Contact Info

Product

Resources

About